Conclusion. Alport syndrome patients experienced comparable dialysis and renal transplant outcomes to matched nonAlport ESKD controls in the contemporary cohort due to relatively greater improvements in outcomes for non-Alport ESKD patients over time. Post-transplant anti-GBM disease was rare.
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I N T R O D U C T I O N
Alport syndrome is a rare inheritable renal disorder characterized by sensorineural deafness, progressive renal dysfunction and, sometimes, ocular abnormalities [1] [2] [3] [4] [5] [6] [7] . The condition is caused by mutations of genes encoding three collagen IV alpha chains [8] [9] [10] [11] [12] [13] , most commonly COL4A5 situated on the X chromosome [14] [15] [16] [17] [18] accounting for 85% of cases [19] . Males with this form of disease express a more severe phenotype [20] [21] [22] [23] . Transplantation of a renal allograft with a normal glomerular basement membrane (GBM) into a patient with Alport syndrome exposes them to a novel GBM collagen antigen and can result in de novo anti-GBM antibody disease in the graft [20, [24] [25] [26] [27] [28] .
The proportion of end-stage kidney disease (ESKD) patients commencing renal replacement therapy (RRT) due to Alport syndrome varies considerably between countries [29] . Most patients with Alport syndrome commence RRT in early adulthood, particularly males who typically start RRT a decade earlier than females [29] . However, the predictors and outcomes of patients with ESKD secondary to Alport syndrome following RRT commencement have not been well studied, with many reports being limited by small patient numbers, single-centre design, use of variably contemporaneous cohorts and a predominant focus on post-transplant anti-glomerular basement antibody disease without reporting other clinically important outcomes [30] [31] [32] [33] [34] [35] [36] [37] [38] .
The aim of this study was to investigate the characteristics, treatments and outcomes of all cases of RRT-treated ESKD due to Alport syndrome in the Australian and New Zealand dialysis populations, using data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.
M AT E R I A L S A N D M E T H O D S

Patient population
The analyses in this study were based on patients starting RRT for ESKD whose primary renal disease was reported to be Alport syndrome by their treating nephrologists between 2 September 1965 and 31 December 2010 using data from the ANZDATA Registry. Patients with Alport syndrome were compared with matched controls with ESKD due to an alternative primary renal diagnosis.
The data were collected throughout the calendar year by medical and nursing staff in each renal unit and submitted every 6 months to the ANZDATA Registry until 2005 and then annually thereafter. The data collected include demographic data, cause of primary renal disease, RRT dates, modalities and outcomes. For patients who started RRT after 1996, smoking status, body mass index (BMI), late referral (defined as commencement of dialysis within 3 months of referral to a nephrologist) and comorbidities (chronic lung disease, peripheral vascular disease, cerebral vascular disease, cardiovascular disease and diabetes mellitus) were also collected. Dialysis and transplant eras were determined by the dialysis and transplant commencement dates, respectively: 1965-75, 1976-85, 1986-95, 1996-2000, 2001-05 and 2006-10. For each of the dialysis and renal transplant cohorts, Alport ESKD patients were matched with controls with alternative causes of ESKD by propensity score matching [39] , enabling optimized examination of the effect of Alport syndrome upon clinical outcomes independent of other factors. Patients were divided into two different cohorts according to their year of RRT commencement (early cohort: 1965-96; contemporary cohort: 1997-2010). The propensity score was calculated by using multivariable logistic regression, in which Alport syndrome was the outcome variable. For the early cohort, the independent variables included in the regression model were age, gender, ethnicity, treatment era, initial dialysis modality (HD versus PD for dialysis patients) and, for patients receiving renal transplants, donor source and time from dialysis to renal transplant. For the contemporary cohort, smoking status, BMI, late referral (only for dialysis patients) and initial comorbidities were also added as the independent variables when matching. The availability of these additional comorbidities from 1996 onwards defined the time periods of the early and contemporary cohorts. The derived propensity scores were then used to match Alport syndrome patients with controls using 1:1 matching without replacement.
The primary outcomes examined were patient survival on dialysis, renal transplant patient survival following first transplantation and renal allograft survival in which death with a functioning allograft was treated as an event. Survival analyses were restricted to Alport ESKD patients and matched nonAlport ESKD controls.
Statistical analysis
Results were expressed as frequencies and percentages for categorical variables, mean ± standard deviation for continuous normally distributed variables and median (interquartile range, IQR) for continuous variables that were not normally distributed. Categorical data were compared using Chi-square tests. Continuous normally distributed data were compared using two-tailed unpaired t-tests. Continuous non-normally distributed data were compared using Mann-Whitney tests. Time-to-event analyses were performed by Kaplan-Meier and multivariate Cox proportional hazards analyses. In light of the possibility of informative censoring due to differential transplantation rates between ESKD patients with and without Alport syndrome, Cox proportional hazards survival analysis using a competing risks approach was also performed for dialysis patient survival analyses. This involved fitting the Cox model on an augmented data set, as described by Lunn and McNeil [40] . Data were analysed using the software package PASW Statistics for Windows release 18.0 (SPSS Inc., North Sydney, Australia) and Stata/SE version 12.0 (StataCorp., College Station, TX). P-values <0.05 were considered statistically significant.
R E S U LT S
Patient characteristics
A total of 296 (0.5%) patients commenced RRT for ESKD secondary to Alport syndrome during the study period. Twenty-one (7.1%) Alport ESKD patients and 1464 (2.5%) non-Alport ESKD patient received pre-emptive living donor renal transplant (P < 0.001). Median (IQR) follow-up times in the Alport and non-Alport control groups were 10 Figure 1A ). Using a competing risk approach to take into account differential rates of renal transplantation between the Alport and non-Alport control groups (91 and 79%, P = 0.006), Alport ESKD was associated with significantly lower mortality on dialysis (HR: 0.42, 95% CI: 0.21-0.83, P = 0.01) in the early cohort.
Contemporary cohort (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . Death during dialysis treatment occurred in 14 (10%) Alport syndrome patients and 12 (9%) matched non-Alport controls. The causes of death were cardiac (64 versus 42%), withdrawal from dialysis (29 versus 25%), vascular (0 versus 25%) and malignancy (7 versus 8%; P = 0.25). The renal transplant rate in Alport patients was comparable to that of matched non-Alport controls (71 versus 63%, P = 0.16). The survival of patients with Alport syndrome on dialysis was comparable to that of matched control dialysis patients with other causes of ESKD (HR: 1.42, 95% CI: 0.65-3.11, P = 0.38) ( Figure 1B ).
Alport patients only (1965-2010).
In patients with Alport syndrome, male patients started dialysis at a younger mean age than female patients (30.6 ± 13.4 versus 39.8 ± 15.8, P < 0.001, 95% CI: −13.28 to −5.07). The median survival time of male Alport ESKD patients (11.23 years, 95% CI: 6.60-15.85 years) was comparable to that of female Alport ESKD patients (8.24 years, 95% CI: 7.25-9.23 years, P = 0.43). When only patients with Alport syndrome were considered, death on dialysis was only independently predicted by older age (HR per decade = 1.68, 95% CI: 1.21-2.32, P = 0.002) after adjusting for gender, race and dialysis era.
Renal transplant graft survival A total of 243 (82%) ESKD patients with Alport syndrome received 317 renal allografts during the study period. Seventyfour patients were retransplanted. The patients' baseline characteristics before and after matching are shown in Table 2 .
Early cohort . A total of 111 ESKD patients with Alport syndrome received 174 renal allografts, and 111 nonAlport controls received 171 renal allografts during the study period. Graft failure occurred in 93 grafts in Alport syndrome and 101 grafts in matched non-Alport controls. The causes of graft failure in the Alport syndrome and matched non-Alport control groups were chronic allograft nephropathy (57 versus 45%, respectively), acute rejection (18 versus 18%), hyperacute rejection (0 versus 1%), renal artery thrombosis (0 versus 1%), renal vein thrombosis (2 versus 4%), glomerulonephritis (2 versus 7%), BK virus-associated nephropathy (1 versus 0%) and other (20 versus 25%) (P = 0.270). Alport syndrome appeared to be associated with superior renal allograft survival (to that of matched non-Alport controls) in the early cohort although Cox regression demonstrated a borderline significant difference (HR: 0.74, 95% CI: 0.54-1.01, P = 0.05) ( Figure 2A ).
Contemporary cohort (1996-2010).
A total of 132 ESKD patients with Alport syndrome received 143 renal allografts, and 132 matched non-Alport controls received 138 renal allografts during the study period. Graft failure occurred in 21 grafts in Alport syndrome and 17 grafts in matched nonAlport control patients. The causes of graft failure in the Alport syndrome and matched non-Alport control groups were chronic allograft nephropathy (57 versus 47%, respectively), hyperacute rejection (0 versus 6%), renal vein thrombosis (5 versus 0%), glomerulonephritis (0 versus 12%), BK virus-associated nephropathy (5 versus 0%) and other (33 versus 35%) (P = 0.356). For first grafts, the survival of Alport syndrome ESKD patients was comparable to that of matched non-Alport controls (HR: 1.01, 95% CI: 0.57-1.79, P = 0.98) ( Figure 2B ).
Alport patients only (1965-2010).
When only Alport ESKD patients were considered, more recent transplant era was the only significant predictor of graft survival after adjusting for age, race, gender, donor source and time from dialysis to renal transplant.
Renal transplant patient survival Early cohort . The survival of Alport syndrome patients following first renal transplantation was superior to that of matched non-Alport control ESKD patients (HR: 0.43, 95% CI: 0.28-0.66, P < 0.001) ( Figure 3A) . The causes of death in the Alport syndrome (n = 33) and matched non-Alport control groups (n = 59) were cardiac (30 versus 39%, Contemporary cohort (1996-2010). The survival of Alport syndrome patients following first renal transplantation was comparable to that of matched non-Alport control ESKD patients (HR: 0.67, 95% CI: 0.26-1.73, P = 0.41) ( Figure 3B ). The causes of death in the Alport syndrome (n = 7) and matched non-Alport control groups (n = 11) were cardiac (14 versus 0%, respectively), vascular (0 versus 9%), malignancy (57 versus 36%), infection (14 versus 46%), withdrawal (14 versus 0%) and other (0 versus 9%) (P = 0.182).
Alport patients only . When only Alport syndrome ESKD patients were considered, younger age at transplantation and more recent transplant era were the only independent predictors of renal transplant survival after adjusting for donor source, gender, race and time from dialysis to renal transplant.
Parenthood
Four female patients with Alport syndrome became pregnant after kidney transplantation. Two pregnancies were lost due to spontaneous abortions before 20 weeks, with the remaining four pregnancies leading to four live deliveries. Fortyone male patients with Alport syndrome became fathers after commencing RRT, with a total of 56 children born. The majority of these men had functioning grafts at the time of fatherhood. Of the 60 children of Alport syndrome patients, two were born with fetal abnormalities (not specified). Eight patients died after parenthood, with the youngest child of them being 8 at the time of parental death. F I G U R E 1 : Kaplan-Meier survival curves of patients with Alport syndrome and matched control patients commencing dialysis in Australia and New Zealand (A) between 1965 and 1995 (log-rank score = 5.75, P = 0.011) and (B) between 1996 and 2010 (log-rank score = 0.77, P = 0.380). The characteristics of patients with other causes of ESKD are shown for both the entire group and the propensity score-matched control subgroup. ATSI, Aboriginal and Torres Strait Islander; eGFR, estimated glomerular filtration rate; MPI, Maori and Pacific Islander.
D I S C U S S I O N
This retrospective analysis examined the characteristics, treatments and outcomes of 296 patients with RRT-treated Alport syndrome ESKD compared with matched non-Alport controls. Alport syndrome accounted for 0.5% of all cases of ESKD and was found to be associated with superior dialysis patient survival, superior post-transplant patient survival and potentially superior renal allograft survival to matched controls with other causes of ESKD during the period 1965-95. However, dialysis and renal transplant outcomes were comparable between RRT-treated Alport syndrome ESKD and matched non-Alport controls during the more recent period 1996-2010 due to relatively greater improvements in outcomes for non-Alport ESKD patients over time. Post-transplant anti-GBM antibody disease was extremely rare. The observed RRT-treated Alport syndrome ESKD prevalence of 0.5% is similar to those of 0.2 and 0.6% reported from the USRDS [41] and ERA-EDTA [29] registries, respectively. However, significant variation has been reported between different countries [29] and between adult and paediatric populations with Alport syndrome accounting for up to 3% of US paediatric patients with ESKD [41] . Compatible with clinical guidelines [42, 43] and previous findings in other Alport syndrome patient cohorts of effectiveness, delayed ESKD onset and increased survival attributed to renin-angiotensin-aldosterone system (RAAS) antagonism [44] [45] [46] [47] , an increased age at ESKD onset was observed between the early and contemporary Alport syndrome groups in this study (29.3 versus 36.6 years). A similar change in age at RRT onset was, however, also observed in those without Alport syndrome (47.7 versus 58.7 years). This raises the possibility that the benefit derived and observed delay in ESKD onset attributed to RAAS inhibitor therapy may not be peculiar to those with Alport syndrome as suggested in previous studies which did not report, as we have, whether such changes were also observed in non-Alport control groups [20, 44, 47] . It is also possible that other therapies or changes to clinical practice may have contributed to delayed ESKD onset. Future randomized control trial data are anticipated to aid clarification [48] .
Patients with Alport syndrome were more likely to be male, Caucasian, referred to renal units early and treated with preemptive living donor renal transplantation. In the contemporary cohort where comorbidity data were available, Alport syndrome patients were less likely to be diabetic (reflecting the high burden of diabetic nephropathy in non-Alport ESKD) and have cardiovascular and chronic lung disease and were more likely to be current smokers ( possibly reflecting association with a younger male population). Interestingly, the proportion of males with Alport syndrome decreased between the early and contemporary cohorts for both incident RRT-treated ESKD (80 versus 67%) and renal transplantation (84 versus 74%). Although at-risk female carriers of Alport syndrome, particularly due to COL4A5 mutations, might not be expected to have a high prevalence of ESKD among younger age groups, the cumulative prevalence of RRT-treated ESKD likely increases with increasing age as the relative protective effect of lyonisation diminishes. Furthermore, the clinical phenotypes of affected males and females are somewhat different, such that the findings of this study may have reflected the outcomes of females with poor renal outcomes while not capturing the likely majority of affected females not proceeding to ESKD. The finding that women with Alport syndrome can be significantly affected in addition to men is however clinically important.
The findings of superior survival of patients with Alport syndrome on dialysis or following renal transplantation in the early cohort (1965-95) is in keeping with that of a recently published European registry matched cohort study of 456 patients with Alport syndrome receiving RRT between 1990 and 2009 [20] . The mean survival of patients on dialysis (∼9 years) was similar to that observed in this study (9.78 years), as were the 10-year renal transplant patient and allograft survival rates (∼92 and 54%, respectively). Although the authors of the European study suggested that the superior survival of patients with Alport syndrome on RRT was due to a lower burden of comorbid disease, they did not test this hypothesis due to the lack of availability of comorbidity data. In this study, patients with Alport syndrome were appreciably less likely to have comorbid illnesses, such as diabetes mellitus, cardiovascular disease and chronic lung disease, compared with patients with other non-Alport forms of ESKD. After propensity score matching for these parameters in a contemporary cohort (1996-2010; similar to the 1990-2009 observation period of the European study) in whom comorbidity data were available, the survival advantage of Alport syndrome was no longer apparent in either dialysis patients or renal transplant recipients, thus supporting the European study's hypothesis. It is also conceivable that the sample size of the contemporary cohort in this study did not allow sufficient statistical power to detect a small survival advantage of Alport syndrome following comorbidity adjustment.
Other studies of Alport syndrome patients undergoing renal transplantation have been limited to single-centre reports [30] [31] [32] [33] [34] [35] [36] [37] [38] and have focussed primarily on early renal transplantation outcomes, particularly with respect to the occurrence of de novo anti-GBM antibody disease. Although these prior cohorts have estimated an incidence rate of anti-GBM antibody disease of 1-5% [28, 35, 49, 50] , this study only observed a single case out of 317 renal allografts (0.3%). The explanation for the lower observed incidence in this study may relate to different transplant immunosuppression protocols or different thresholds for diagnosis and coding of post-transplant anti-GBM antibody disease.
Pregnancy after renal transplantation [51] [52] [53] [54] or while on chronic RRT [55, 56] is less frequent and less likely to be successful than in the general population. The finding of four successful live births from six reported pregnancies in four female Alport syndrome patients following renal transplantation and no pregnancies in female patients undergoing RRT are consistent with this paradigm. The present report also observed that, of the 60 patients with Alport syndrome (56 male, 4 female) who bore offspring during the study period, 8 died after a minimum period of 8 years. Paternity may, however, be underreported.
The strengths of this study included its very large sample size and inclusiveness. We included all Alport syndrome ESKD patients receiving RRT in Australia and New Zealand during the study period, such that a variety of centres were included with varying approaches to the treatment of Alport syndrome disease and ESKD. This greatly enhanced the external validity of our findings. These strengths should be balanced against the study's limitations, which included limited depth of data collection. ANZDATA does not collect important information, such as extra-renal features of Alport syndrome, severity of comorbidities, concomitant medications, patient compliance, individual unit management protocols and laboratory values. Although we adjusted for a number of patient characteristics, the possibility of residual confounding could not be excluded. It is possible that additional patients with Alport syndrome were not recorded as having this condition in the ANZDATA Registry though the effect of this on our results is difficult to estimate. Patients were reported as having Alport syndrome based upon diagnosis by their treating clinicians, which frequently involved renal biopsy. It is not known what proportion of these patients had a confirmed molecular genetic diagnosis of Alport Syndrome as the ANZDATA Registry does not collect this information. Despite the frequent use of renal histology in the diagnosis, classification bias could not be excluded, such that some patients reported as having Alport syndrome may have had an alternative renal diagnosis. In common with other registries, ANZDATA is a voluntary registry, and there is no external audit of data accuracy, including the diagnosis of Alport syndrome.
In conclusion, Alport syndrome is an uncommon cause of ESKD and is associated with younger age at RRT commencement, male gender, earlier referral and a higher likelihood of receiving renal transplantation. Over time, the proportion of male Alport syndrome patients decreased and the average age at RRT commencement increased. After adjustment for comorbidity, RRT-treated ESKD patients with Alport syndrome had comparable dialysis and renal transplant outcomes to those of matched non-Alport controls in a contemporary cohort (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) and superior outcomes in an early cohort (1965-96). Post-transplant anti-GBM antibody disease was a rare complication in patients with Alport syndrome. This information may assist with counselling of patients with Alport syndrome undergoing RRT.
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